Translation of an experimental oral vaccine formulation into a commercial product

Carter, K.C. and Ferro, V.A. and Alexander, J. and Mullen, A. (2006) Translation of an experimental oral vaccine formulation into a commercial product. Methods, 38 (2). pp. 65-68. ISSN 1046-2023 (https://doi.org/10.1016/j.ymeth.2005.11.001)

Full text not available in this repository.Request a copy

Abstract

An effective experimental vaccine may fail to become a therapeutic reality for a number of scientific, regulatory or commercial reasons. In this review, we share some of our personal experiences as University-based researchers and provide an account of some of the problems that we have encountered during preliminary scale-up and assessment of an oral influenza vaccine formulation. Many of the problems we have faced have been non-scientific and related to identifying project-funding sources, finding suitable contract manufacturing companies that are GMP compliant, and protecting intellectual property generated from the scientific studies. The review is intended as a practical guide that will allow other researchers to adopt effective strategies to permit the translation of an effective experimental formulation to a viable commercial product.

ORCID iDs

Carter, K.C., Ferro, V.A. ORCID logoORCID: https://orcid.org/0000-0003-1967-3603, Alexander, J. and Mullen, A. ORCID logoORCID: https://orcid.org/0000-0001-7475-5543;
CORE (COnnecting REpositories)